Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model.

× No keyword cloud information.

21 in total

Review 1. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.

Authors: Ting-Chao Chou
Journal: Pharmacol Rev Date: 2006-09 Impact factor: 25.468

2. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors: T C Chou; P Talalay
Journal: Adv Enzyme Regul Date: 1984

3. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound.

Authors: Felix Kratz; André Warnecke; Karin Scheuermann; Cornelia Stockmar; Jürgen Schwab; Peter Lazar; Peter Drückes; Norbert Esser; Joachim Drevs; Didier Rognan; Caterina Bissantz; Caterina Hinderling; Gerd Folkers; Iduna Fichtner; Clemens Unger
Journal: J Med Chem Date: 2002-12-05 Impact factor: 7.446

4. The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage.

Authors: Dirk Lebrecht; Andrea Geist; Uwe-Peter Ketelsen; Jörg Haberstroh; Bernhard Setzer; Felix Kratz; Ulrich A Walker
Journal: Int J Cancer Date: 2007-02-15 Impact factor: 7.396

5. Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin.

Authors: F Kratz; G Ehling; H M Kauffmann; C Unger
Journal: Hum Exp Toxicol Date: 2007-01 Impact factor: 2.903

6. Acid pH in tumors and its potential for therapeutic exploitation.

Authors: I F Tannock; D Rotin
Journal: Cancer Res Date: 1989-08-15 Impact factor: 12.701

7. INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model.

Authors: R Graeser; N Esser; H Unger; I Fichtner; A Zhu; C Unger; F Kratz
Journal: Invest New Drugs Date: 2009-01-08 Impact factor: 3.850

8. Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models.

Authors: P A Trail; D Willner; S J Lasch; A J Henderson; R S Greenfield; D King; M E Zoeckler; G R Braslawsky
Journal: Cancer Res Date: 1992-10-15 Impact factor: 12.701

Review 9. DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials.

Authors: Felix Kratz
Journal: Expert Opin Investig Drugs Date: 2007-06 Impact factor: 6.206

10. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

Authors: Y Matsumura; H Maeda
Journal: Cancer Res Date: 1986-12 Impact factor: 12.701

8 in total

Review 1. Protein based therapeutic delivery agents: Contemporary developments and challenges.

Authors: Liming Yin; Carlo Yuvienco; Jin Kim Montclare
Journal: Biomaterials Date: 2017-04-21 Impact factor: 12.479

2. Morphine modulates doxorubicin uptake and improves efficacy of chemotherapy in an intracranial xenograft model of human glioblastoma.

Authors: Martina da Ros; Anna Lisa Iorio; Dario Consolante; Francesco Cardile; Monica Muratori; Ornella Fantappiè; Maurizio Lucchesi; Milena Guidi; Claudio Pisano; Iacopo Sardi
Journal: Am J Cancer Res Date: 2016-02-15 Impact factor: 6.166

3. Anti-cancer effects of novel doxorubicin prodrug PDOX in MCF-7 breast cancer cells.

Authors: Jue Zhang; Liang He; Xia-Fei Geng; Raymond A Firestone; Ya-Ping Hong; Yan Li
Journal: J Huazhong Univ Sci Technolog Med Sci Date: 2014-08-19

Review 4. Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy.

Authors: Zhibo Liu; Xiaoyuan Chen
Journal: Chem Soc Rev Date: 2016-03-07 Impact factor: 54.564

5. Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastoma.

Authors: Luis Marrero; Dorota Wyczechowska; Alberto E Musto; Anna Wilk; Himanshu Vashistha; Adriana Zapata; Chelsey Walker; Cruz Velasco-Gonzalez; Christopher Parsons; Scott Wieland; Daniel Levitt; Krzysztof Reiss; Om Prakash
Journal: Neoplasia Date: 2014-10-23 Impact factor: 5.715

Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model.